Devex opinion piece
The Trump administration’s “America First” global health strategy proudly showcases lenacapavir, a twice-yearly injectable for HIV prevention, as proof of US innovation and leadership. Yet in practice, $11 billion in US health aid is now flowing through 15 bilateral agreements that fail to include a single HIV prevention target.
Omitting HIV prevention targets from these deals will be devastating to the affordability and scale-up of lenacapavir. African leaders can change that.
Read the full opinion piece here.
/free registration is required/
Source : Devex
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.